Pain
 » 
David Finn
David Finn
A phoneA letter

David Finn

Professor of pharmacology and therapeutics

Role in PharmNovo: Scientific advisor.

University: Galway Neuroscience Centre.

Resumé: David Finn is Professor of Pharmacology and Therapeutics, Science Foundation Ireland Principal Investigator and Co-Founder and Co-Director of the Centre for Pain Research (link) at the National University of Ireland (NUI) Galway. Professor Finn graduated with a BSc (Hons) in Biotechnology from NUI Galway in 1997 and a PhD in Neuroscience from the University of Bristol in 2001. From 2001 to 2004, Professor Finn worked as a Post-doctoral Research Fellow at the Institute of Neuroscience, University of Nottingham. In 2004, he was appointed to a Lectureship in the Department of Physiology, NUI Galway, and to a Personal Professorship in Pharmacology and Therapeutics in 2014.  Professor Finn’s research focuses on the understanding of the neurobiology and treatment of pain and psychiatric disorders including anxiety and depression.  

Professor Finn is Past-President of the Irish Pain Society and is currently President-Elect of the International Cannabinoid Research Society. He is also a member of the Task Forces of both the International Association for the Study of Pain and the European Pain Federation on Cannabis and Cannabinoids for Chronic Pain, and he sits on the Scientific Advisory Panel of the European College of Neuropsychopharmacology as well as the Editorial Boards of the Journal of Psychopharmacology,  Brain Research and Frontiers in Neuropharmacology (link).

Member of:

Latest news

View all
July 17, 2024

17.5m EUR blended funding from EIC

PharmNovo is very pleased to announce that we have been awarded a 2.5m EUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.

Read more
June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

Read more
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

Read more